Silence Therapeutics plc’ Partner, Quark Pharmaceuticals Inc., Extends its Agreement With Pfizer Inc. to Develop one of Its Compounds Containing AtuRNAi in a New Indication

LONDON, May 3, 2012 /PRNewswire/ --Silence Therapeutics Plc (AIM: SLN), a leading international RNAi therapeutics company, notes that its partner,…
Read the full story: BioSpace.com Featured News